How effective is Enfortumab?

Enfortumab vedotin-ejfv is a treatment drug for advanced urothelial carcinoma (urothelial carcinoma). It is an antibody-drug combination that combines monoclonal antibodies with cytotoxins to kill cancer cells by specifically targeting the Nectin-4 protein on the surface of cancer cells. The following is a preliminary explanation of the efficacy of ennosumab based on data as of September 2021 and possible clinical trial data.

1. Clinical trials and efficacy data: The efficacy evaluation of ennozumab is mainly based on clinical trial data, which will be continuously updated and subject to review and discussion by the medical community. Here are some possible clinical trial data demonstrating the efficacy of ennosumab in patients with advanced urothelial cancer:

Pivotal Trial:EV-301Trial: EV-301 is a Phase III clinical trial in metastatic or locally advanced urothelial carcinoma, comparing The efficacy of ennosumab combined with virginiafil (aflibercept) and chemotherapy drugs (docetaxel or loplatin) in the treatment of refractory patients was studied. Preliminary results show that ennosumab combined with virginiafil is significantly better than chemotherapy in terms of overall survival (OS) and progression-free survival (PFS).

Clinical Trial Data: Other Clinical Trials: Other clinical trials, such as EV-201 and EV-203, also evaluated the efficacy of ennozumab in different treatment settings. These trial results demonstrate the anticancer activity of ennosumab in diverse patient populations.

2. Efficacy evaluation indicators

In clinical trials, the following indicators are usually used to evaluate the efficacy of ennozumab:

Overall Survival (Overall Survival, OS): The time from the start of treatment to death or last follow-up.

Progression-Free Survival (PFS): The time from the start of treatment to disease progression, death or last follow-up.

Overall Response Rate (Overall Response Rate, ORR): The proportion of patients who experience complete or partial tumor shrinkage.

Duration of Response (Duration of Response, DoR): The duration of a complete or partial response.

3. Clinical data analysis

According to clinical trial data, ennosumab has shown significant efficacy in patients with advanced urothelial cancer. Its superiority compared with chemotherapy drugs in the EV-301 trial was demonstrated by significantly prolonged overall survival and progression-free survival, as well as a higher overall response rate. These results suggest that ennosumab may become an important therapeutic option in the treatment of advanced urothelial carcinoma.

4. Side effects and safety

Although ennosumab has excellent efficacy, it may also cause some side effects during use. According to clinical trial data, common side effects include fatigue, nausea, skin reactions, loss of appetite, etc. In addition, severe immune reactions and infections can occur, so close monitoring and doctor's advice are needed when using the drug.

5. Conclusion

Enfortumab vedotin-ejfv is a therapeutic drug for advanced urothelial cancer. According to clinical trial data as of 2021year9month, it has shown significant efficacy in improving overall survival, progression-free survival and overall response rate. However, because drug information may be updated over time, it is recommended that you review the latest clinical trial data and medical literature for more comprehensive and accurate information. Treatment decisions should be made under the guidance of a medical professional.

Ennosumab is not currently available in China, so patients cannot purchase it domestically and need to purchase ennosumab through overseas channels. There are only enromonumab original drugs in foreign countries, and there are no generic drugs. They are mainly Japanese original drugs, and the price is more than 10,000 yuan.